The First Self-Administered Flu Vaccine Receives FDA Approval: FluMist

On September 20, 2024, the United States Food and Drug Administration (FDA) approved FluMist for self-administration or administration by a caregiver. FluMist is approved to prevent influenza caused by influenza virus subtypes A and B in people aged 2 to 49.

A New Era in Flu Vaccination

This development is regarded as an important step toward wider flu vaccination. The FDA approval offers a new convenience in protecting against a disease that affects millions of people each year and can cause serious complications.

Why Does It Matter? What Does Wider Flu Vaccination Mean?

Influenza can cause serious complications each year, particularly in high-risk groups such as older people, children, and people with chronic illnesses. In the United States alone, between 9.3 million and 41 million cases occur annually, resulting in approximately 100 thousand to 710 thousand hospitalizations. Between 2010 and 2023, annual flu deaths ranged from 4,900 to 51,000. These figures show that wider flu vaccination is critical not only for protecting individual health but also for public health.

Approving FluMist for self-administration or administration by a caregiver will make the vaccine more accessible and reduce barriers to vaccination. By removing the need for a doctor's visit, this new administration option may encourage more people to get vaccinated.

What Is FluMist?

FluMist is a nasal flu vaccine containing weakened live influenza virus strains. It is approved to prevent disease caused by influenza virus subtypes A and B in people aged 2 to 49. First approved by the FDA in 2003 for people aged 5-49, its use was expanded in 2007 to include children aged 2-5.

Unlike traditional flu vaccines, FluMist does not require a needle or injection. This offers an important advantage for people afraid of needles. Self-administration or caregiver administration also makes vaccination more flexible and accessible. However, it is important to remember that FluMist requires a prescription.

Who Can Benefit? How Does Administration Work?

FluMist may be administered by a healthcare professional, while people aged 18 and older may administer it themselves or have a caregiver do so. For children aged 2-17, however, it must be administered by a caregiver. The vaccine will be available to order through a third-party online pharmacy and delivered to people's homes after an eligibility assessment.

Safety and Adverse Effects

FluMist's adverse effects are generally mild and short-lived. In children aged 2-6, the most common adverse effect is fever above 38°C, while a runny or congested nose is most common in people aged 2-49. Sore throat has also been reported in adults aged 18-49.

Before the FDA granted this approval, a study assessed whether individuals and caregivers administering FluMist could use it correctly and safely. The results showed that the vaccine could be administered safely at home.

Comprehensive Guidance and Information

Individuals and caregivers ordering FluMist will receive detailed instructions and information documents with the vaccine. These include prescribing information, information for patients and caregivers, and instructions for use, providing comprehensive guidance on storing, administering, and disposing of the vaccine.

The FDA's Innovative Public Health Approach

Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, says the approval offers a new alternative for flu vaccination and contributes to the FDA's mission to improve public health. Noting that regular annual vaccination is the most effective way to prevent influenza, he emphasizes that broad vaccine access is critical to reducing flu-related hospitalization and death.

Conclusion: Greater Access and Flexibility in Flu Vaccination

Making FluMist available for home administration is a step that will contribute substantially to public health by improving access to flu vaccination. Easier vaccination is particularly important for people with busy working lives, travel difficulties, or barriers to healthcare access. The FDA's decision will support a healthier society by increasing awareness of flu vaccination and vaccination rates.